Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more ...

Chemotherapy may soon take a backseat. Experts say targeted therapies—drugs that attack cancer at the genetic level—are ...

EU approves Alexion’s Koselugo for plexiform neurofibromas in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, October 29, 2025, 11:00 Hrs [IST] Alexion, AstraZene ...

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...

New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with ...

The data, first presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showed that the phase 3 ...

A major international study led by UCL researchers has found that combining two cancer drugs could substantially slow the progression of a severe and often deadly form of prostate cancer in men with ...

Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership ...